An Open-Labeled Non-Randomized Phase I Study of 17-N-Allylamino-17-Demethoxy Geldanamycin (17AGG) Administered With Irinotecan (CPT) in Patients With Advanced Solid Tumors.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Tanespimycin (Primary) ; Irinotecan
- Indications Solid tumours
- Focus Adverse reactions
- 04 Jun 2013 Biomarkers information updated
- 21 Sep 2007 Status changed from recruiting to completed.
- 08 Nov 2005 New trial record.